COVID-19 IgG/IgM Rapid Test P2002
This product is used for the qualitative testing of novel coronavirus (2019-nCoV) IgM and IgG antibodies in human serum, plasma or whole blood in vitro, and can be used for clinical auxiliary diagnosis of novel coronavirus (2019-nCoV) infection. The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
COVID-19 IgG/IgM Rapid Test P2004
The GenSure™ COVID-19 Antigen Rapid Test Kit is a rapid direct binding test for the visual detection of SARS-CoV-2 antigen in human nasal swab specimens as an aid in the diagnosis of SARS-CoV-2 infection.
GenSure™ COVID-19 Antigen Rapid Test Kit P2004s
The GenSure™ COVID-19 Antigen Rapid Test Kit is a polymer immunochromatographic technology and double antibody sandwich principle that is intended for the qualitative detection of the N protein antigen from SARS-CoV-2 in human nasal swab specimens directly. Testing is limited to laboratories and medical institutions.
COVID-19 Neutralizing Antibody Test(Fluorescence) P2005
The GenSure™ COVID-19 19 Neutralizing Antibody Test (Fluorescence) is for in vitro qualitative detection of the neutralizing antibodies against SARS-CoV-2 in human serum, plasma or whole blood.
COVID-19 Neutralizing Antibody Test(Latex) P2006
The GenSure™ COVID-19 Neutralizing Antibody Rapid Test (Latex) is a lateral flow assay intended for the qualitative detection of RBD antibody to SARS-CoV-2 in human serum, plasma or whole blood in vitro.
COVID-19/Flu A+B Antigen Combo Rapid Test P2007
The COVID-19/Flu A/B Antigen Combo Rapid Test is an in vitro rapid diagnostic immunochromatographic assay intended for the simultaneous qualitative detection and differentiation of the antigens from novel coronavirus, influenza A and influenza B in direct nasal swab specimens from individuals suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider. Clinical signs and symptoms of respiratory viral infection due to novel coronavirus and influenza can be similar. It is not intended to detect influenza C.
SARS-CoV-2 N / S IgG Combo Rapid Test P2010
The SARS-CoV-2 N / S IgG Combo Rapid Test is used for the qualitative testing of SARS-CoV-2 IgG antibody to nucleocapsid (N) and spike (S) protein in human serum, plasma or whole blood in vitro. It is used to assist in the diagnosis of SARS-CoV-2 infection and to detect whether the SARS-CoV-2 IgG antibody to N / S protein is generated in the blood after injected with the vaccine.